Krebs Historical Balance Sheet

KREBSBIO

66.37 3.24 4.65%

Trend analysis of Krebs Biochemicals and balance sheet accounts such as Other Current Liab of 394.7 M provides information on Krebs Biochemicals' total assets, liabilities, and equity, which is the actual value of Krebs Biochemicals and to its prevalent stockholders. By breaking down trends over time using Krebs Biochemicals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Krebs Biochemicals and latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krebs Biochemicals and is a good buy for the upcoming year.

Krebs Biochemicals Inventory

145.69 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About Krebs Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Krebs Biochemicals and at a specified time, usually calculated after every quarter, six months, or one year. Krebs Biochemicals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Krebs Biochemicals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Krebs currently owns. An asset can also be divided into two categories, current and non-current.

Krebs Biochemicals Balance Sheet Chart

As of now, Krebs Biochemicals' Net Receivables is decreasing as compared to previous years. The Krebs Biochemicals' current Non Current Liabilities Total is estimated to increase to about 2.8 B, while Common Stock Shares Outstanding is projected to decrease to under 15.6 M.

Common Stock Shares Outstanding Total Assets Short Long Term Debt Total Other Current Liab

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Krebs Biochemicals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Krebs Biochemicals and books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most accounts from Krebs Biochemicals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Krebs Biochemicals and current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	1.8B	2.4B	2.7B	2.9B
Total Assets	1.7B	1.8B	1.6B	1.3B

Short Long Term Debt Total Total Assets

Krebs Biochemicals balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Retained Earnings	Intangible Assets	Other Liab
Common Stock Shares Outstanding		0.09	0.64	0.63	0.24	-0.87	0.88	0.54	0.34	-0.03	0.59	-0.63	-0.14	-0.49	0.76	-0.38	0.28	0.37	0.88	-0.56	0.97	-0.27	0.2	-0.91	0.68	0.83
Total Assets	0.09		0.23	0.11	0.03	0.11	0.38	0.16	0.21	-0.14	0.76	0.47	-0.26	0.73	0.27	0.29	0.32	0.33	0.4	0.68	0.21	0.02	-0.32	-0.21	-0.18	-0.08
Short Long Term Debt Total	0.64	0.23		0.91	0.16	-0.79	0.63	0.97	0.24	-0.2	0.72	-0.15	-0.43	-0.04	0.96	-0.18	0.06	0.69	0.79	-0.17	0.7	-0.25	0.1	-0.84	0.32	0.55
Other Current Liab	0.63	0.11	0.91		0.1	-0.76	0.6	0.92	0.09	-0.23	0.61	-0.21	-0.41	-0.12	0.88	-0.24	0.11	0.49	0.71	-0.28	0.7	-0.29	0.04	-0.79	0.5	0.65
Total Current Liabilities	0.24	0.03	0.16	0.1		-0.36	0.22	0.08	0.55	-0.08	0.07	-0.3	0.1	-0.23	0.15	0.61	-0.05	-0.05	0.37	0.13	0.15	0.76	0.12	-0.19	-0.2	-0.11
Total Stockholder Equity	-0.87	0.11	-0.79	-0.76	-0.36		-0.71	-0.72	-0.35	0.14	-0.43	0.64	0.24	0.59	-0.83	0.25	-0.11	-0.42	-0.81	0.6	-0.84	0.17	-0.26	0.92	-0.56	-0.73
Property Plant And Equipment Net	0.88	0.38	0.63	0.6	0.22	-0.71		0.54	0.26	-0.08	0.8	-0.5	-0.11	-0.16	0.79	-0.33	0.37	0.43	0.88	-0.29	0.87	-0.19	0.12	-0.85	0.56	0.64
Net Debt	0.54	0.16	0.97	0.92	0.08	-0.72	0.54		0.05	-0.22	0.65	-0.08	-0.43	0.0	0.9	-0.23	-0.08	0.65	0.7	-0.2	0.6	-0.24	0.06	-0.75	0.27	0.48
Accounts Payable	0.34	0.21	0.24	0.09	0.55	-0.35	0.26	0.05		-0.07	0.21	-0.29	-0.19	-0.18	0.26	0.5	0.21	0.11	0.4	0.16	0.33	0.08	-0.03	-0.34	0.05	0.09
Cash	-0.03	-0.14	-0.2	-0.23	-0.08	0.14	-0.08	-0.22	-0.07		-0.24	-0.14	0.86	-0.09	-0.22	-0.28	-0.31	-0.05	-0.19	0.0	-0.06	-0.04	0.48	0.15	0.25	0.03
Non Current Assets Total	0.59	0.76	0.72	0.61	0.07	-0.43	0.8	0.65	0.21	-0.24		0.08	-0.39	0.37	0.78	-0.1	0.34	0.59	0.81	0.17	0.68	-0.2	-0.15	-0.7	0.19	0.38
Non Currrent Assets Other	-0.63	0.47	-0.15	-0.21	-0.3	0.64	-0.5	-0.08	-0.29	-0.14	0.08		-0.27	0.81	-0.3	0.33	-0.13	0.05	-0.33	0.7	-0.49	0.06	-0.35	0.47	-0.63	-0.52
Cash And Short Term Investments	-0.14	-0.26	-0.43	-0.41	0.1	0.24	-0.11	-0.43	-0.19	0.86	-0.39	-0.27		-0.14	-0.38	-0.2	-0.23	-0.25	-0.33	-0.01	-0.24	0.3	0.44	0.32	0.12	-0.15
Net Receivables	-0.49	0.73	-0.04	-0.12	-0.23	0.59	-0.16	0.0	-0.18	-0.09	0.37	0.81	-0.14		-0.09	0.27	0.11	0.22	-0.18	0.86	-0.36	0.1	-0.34	0.31	-0.48	-0.46
Non Current Liabilities Total	0.76	0.27	0.96	0.88	0.15	-0.83	0.79	0.9	0.26	-0.22	0.78	-0.3	-0.38	-0.09		-0.26	0.23	0.66	0.84	-0.24	0.8	-0.26	0.08	-0.93	0.45	0.64
Inventory	-0.38	0.29	-0.18	-0.24	0.61	0.25	-0.33	-0.23	0.5	-0.28	-0.1	0.33	-0.2	0.27	-0.26		-0.1	-0.23	-0.12	0.67	-0.36	0.65	-0.34	0.3	-0.62	-0.6
Other Current Assets	0.28	0.32	0.06	0.11	-0.05	-0.11	0.37	-0.08	0.21	-0.31	0.34	-0.13	-0.23	0.11	0.23	-0.1		0.24	0.22	0.05	0.34	-0.2	0.11	-0.27	0.4	0.46
Other Stockholder Equity	0.37	0.33	0.69	0.49	-0.05	-0.42	0.43	0.65	0.11	-0.05	0.59	0.05	-0.25	0.22	0.66	-0.23	0.24		0.51	0.04	0.46	-0.32	0.48	-0.55	0.25	0.39
Total Liab	0.88	0.4	0.79	0.71	0.37	-0.81	0.88	0.7	0.4	-0.19	0.81	-0.33	-0.33	-0.18	0.84	-0.12	0.22	0.51		-0.24	0.91	-0.14	0.09	-0.89	0.4	0.63
Total Current Assets	-0.56	0.68	-0.17	-0.28	0.13	0.6	-0.29	-0.2	0.16	0.0	0.17	0.7	-0.01	0.86	-0.24	0.67	0.05	0.04	-0.24		-0.46	0.39	-0.31	0.41	-0.58	-0.63
Common Stock	0.97	0.21	0.7	0.7	0.15	-0.84	0.87	0.6	0.33	-0.06	0.68	-0.49	-0.24	-0.36	0.8	-0.36	0.34	0.46	0.91	-0.46		-0.37	0.17	-0.92	0.7	0.87
Short Term Debt	-0.27	0.02	-0.25	-0.29	0.76	0.17	-0.19	-0.24	0.08	-0.04	-0.2	0.06	0.3	0.1	-0.26	0.65	-0.2	-0.32	-0.14	0.39	-0.37		-0.12	0.3	-0.57	-0.55
Current Deferred Revenue	0.2	-0.32	0.1	0.04	0.12	-0.26	0.12	0.06	-0.03	0.48	-0.15	-0.35	0.44	-0.34	0.08	-0.34	0.11	0.48	0.09	-0.31	0.17	-0.12		-0.13	0.4	0.34
Retained Earnings	-0.91	-0.21	-0.84	-0.79	-0.19	0.92	-0.85	-0.75	-0.34	0.15	-0.7	0.47	0.32	0.31	-0.93	0.3	-0.27	-0.55	-0.89	0.41	-0.92	0.3	-0.13		-0.6	-0.76
Intangible Assets	0.68	-0.18	0.32	0.5	-0.2	-0.56	0.56	0.27	0.05	0.25	0.19	-0.63	0.12	-0.48	0.45	-0.62	0.4	0.25	0.4	-0.58	0.7	-0.57	0.4	-0.6		0.88
Other Liab	0.83	-0.08	0.55	0.65	-0.11	-0.73	0.64	0.48	0.09	0.03	0.38	-0.52	-0.15	-0.46	0.64	-0.6	0.46	0.39	0.63	-0.63	0.87	-0.55	0.34	-0.76	0.88

Click cells to compare fundamentals

Krebs Biochemicals Account Relationship Matchups

Krebs Biochemicals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	16.6M	18.0M	19.6M	21.6M	24.8M	15.6M
Total Assets	1.6B	1.9B	1.7B	1.8B	1.6B	1.3B
Short Long Term Debt Total	1.1B	1.4B	1.8B	2.4B	2.7B	2.9B
Other Current Liab	274.2M	148.1M	237.0M	326.9M	375.9M	394.7M
Total Current Liabilities	481.9M	780.6M	491.0M	618.3M	711.1M	539.4M
Total Stockholder Equity	(427.3M)	(750.9M)	(994.6M)	(1.2B)	(1.1B)	(1.0B)
Property Plant And Equipment Net	1.3B	1.4B	1.5B	1.5B	1.7B	1.1B
Net Debt	998.4M	580.7M	1.8B	2.4B	2.7B	2.9B
Accounts Payable	207.8M	379.1M	152.8M	189.7M	218.2M	207.4M
Cash	7.1M	324K	858K	1.4M	1.6M	1.5M
Non Current Assets Total	1.4B	1.5B	1.6B	1.6B	1.8B	1.4B
Non Currrent Assets Other	57.0M	(1K)	51.5M	89.6M	80.7M	76.6M
Cash And Short Term Investments	10.8M	324K	3.7M	1.4M	1.6M	1.5M
Net Receivables	3.0M	19.5M	6.5M	47.3M	42.5M	66.4M
Liabilities And Stockholders Equity	1.6B	1.9B	1.7B	1.8B	1.6B	1.3B
Non Current Liabilities Total	1.5B	1.9B	2.3B	2.4B	2.7B	2.8B
Inventory	166.0M	255.6M	119.5M	102.4M	92.2M	145.7M
Other Current Assets	34.4M	79.5M	29.7M	23.3M	26.8M	32.0M
Other Stockholder Equity	1.1B	(623.5M)	1.2B	1.3B	1.5B	1.6B
Total Liab	2.0B	2.6B	2.7B	3.0B	3.4B	1.8B
Total Current Assets	214.2M	354.9M	160.6M	174.4M	157.0M	278.7M
Accumulated Other Comprehensive Income	(1.4B)	152.2M	110.5M	114.4M	131.6M	138.2M
Common Stock	166.3M	180.0M	196.2M	215.6M	247.9M	154.5M
Short Term Debt	105.9M	101.7M	101.2M	101.8M	91.6M	128.9M
Current Deferred Revenue	110.5M	(105.9M)	151.8M	115.4M	132.7M	121.4M
Retained Earnings	(1.8B)	(2.3B)	(2.5B)	(2.7B)	(2.4B)	(2.3B)
Intangible Assets	35.1M	28.7M	26.9M	25.0M	28.8M	27.7M
Other Liab	515.7M	501.6M	532.1M	539.0M	619.9M	439.3M
Net Tangible Assets	(161.4M)	(268.4M)	(445.8M)	(769.4M)	(692.5M)	(657.8M)
Other Assets	73.8M	96.0M	82.5M	27.1M	24.4M	23.2M
Long Term Debt	1.0B	1.3B	1.7B	1.8B	2.1B	2.2B
Deferred Long Term Liab	21.8M	19.2M	16.6M	10.2M	9.2M	8.8M
Short Long Term Debt	105.9M	99.9M	99.9M	99.3M	89.4M	113.0M
Property Plant Equipment	1.1B	1.3B	1.4B	1.5B	1.7B	1.1B
Long Term Debt Total	655.1M	1.0B	1.3B	1.7B	2.0B	2.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Other Information on Investing in Krebs Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Krebs Historical Balance Sheet

Krebs Biochemicals Inventory

145.69 Million

About Krebs Balance Sheet Analysis

Krebs Biochemicals Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Krebs Biochemicals balance sheet Correlations

Krebs Biochemicals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Krebs Biochemicals balance sheet Accounts

Also Currently Popular

Other Information on Investing in Krebs Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 0.97	Common Stock Shares Outstanding
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.96	Short Long Term Debt Total
Net Debt	+ 0.92	Other Current Liab
Retained Earnings	+ 0.92	Total Stockholder Equity
Other Current Liab	+ 0.91	Short Long Term Debt Total

Retained Earnings	- 0.93	Non Current Liabilities Total
Retained Earnings	- 0.92	Common Stock
Retained Earnings	- 0.91	Common Stock Shares Outstanding
Retained Earnings	- 0.89	Total Liab
Total Stockholder Equity	- 0.87	Common Stock Shares Outstanding
Retained Earnings	- 0.85	Property Plant And Equipment Net